Regenerative Patch Technologies Presents Clinical Data Demonstrating Long-Term Survival and Function of an Allogenic Bioengineered Cellular Implant in Patients with Advanced Dry Aged-Related Macular Degeneration

Clinical and Histological Results Signal Prolonged Effectiveness in the Treatment of Advanced Retinal Degenerative Diseases MENLO PARK, Calif., Feb. 4, 2022 -- (Healthcare Sales & Marketing Network) -- Regenerative Patch Technologies LLC (RPT) announce... Regenerative Medicine, Ophthalmology Regenerative Patch Technologies, CPCB-RPE1 implant, cell-based implant
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news